Sandra P. D’Angelo

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari et al. · Nature Genetics · 2019 · 4.2K citations · Full text

Cancer Immunosurveillance, Tumor Heterogeneity, Medicine +9

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

Oncology, Pathology, Advanced Soft-tissue Sarcoma +5

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Howard L. Kaufman, Jeffery S. Russell, Omid Hamid et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

Medicine, Metronomic Therapy, Pathology +3

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Troy Z. Horvat, Nelly G. Adel, Thu-Oanh Dang et al. · Journal of Clinical Oncology · 2015 · 1.1K citations · Full text

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine et al. · The Lancet Oncology · 2018 · 716 citations · Full text

Oncology, Ipilimumab Treatment, Clinical Trials +8